Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.

ABSTRACT:

Background

The median age of patients diagnosed with essential thrombocythaemia (ET) is 65-70 years but the management of very elderly patients (aged >80 years) with ET has not been well characterized.

Objective

This study aimed to document the treatment patterns of very elderly patients with ET in a multinational, real-world setting.

Study design

EXELS (Evaluation of Xagrid Efficacy and Long-term Safety) is a phase IV observational study, designed to monitor the efficacy and safety of cytoreductive therapies in clinical practice. In total, 3,598 high-risk patients with ET were recruited from May 2005 to April 2009, in 13 European countries. Data were collected at registration and every 6 months thereafter for 5 years. This analysis was performed on a data-cut taken a

SUBMITTER: Kiladjian JJ 

PROVIDER: S-EPMC3586170 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature